Guggenheim downgraded SpringWorks Therapeutics (SWTX) to Neutral from Buy after the company and Merck KGaA (MKKGY) announced a definitive agreement for Merck KGaA to acquire SpringWorks for $47 per share in cash.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- Amazon sellers pull away from Prime Day, IBM to invest in U.S.: Morning Buzz
- Piper says SpringWorks deal suggests Immunome’s varegacestat ‘undervalued’
- SpringWorks Therapeutics downgraded to In Line from Outperform at Evercore ISI
- SpringWorks Therapeutics downgraded to Equal Weight from Overweight at Barclays
- SpringWorks Therapeutics downgraded to Neutral from Outperform at Wedbush